ADAP vs. IVVD, PSTX, SOPH, STRO, CADL, JSPR, GLUE, MGX, BDTX, and CRBU
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Invivyd (IVVD), Poseida Therapeutics (PSTX), SOPHiA GENETICS (SOPH), Sutro Biopharma (STRO), Candel Therapeutics (CADL), Jasper Therapeutics (JSPR), Monte Rosa Therapeutics (GLUE), Metagenomi (MGX), Black Diamond Therapeutics (BDTX), and Caribou Biosciences (CRBU). These companies are all part of the "biological products, except diagnostic" industry.
Invivyd (NASDAQ:IVVD) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations.
In the previous week, Invivyd had 1 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 14 mentions for Invivyd and 13 mentions for Adaptimmune Therapeutics. Adaptimmune Therapeutics' average media sentiment score of -0.10 beat Invivyd's score of -0.36 indicating that Invivyd is being referred to more favorably in the media.
Adaptimmune Therapeutics received 301 more outperform votes than Invivyd when rated by MarketBeat users. However, 63.64% of users gave Invivyd an outperform vote while only 62.47% of users gave Adaptimmune Therapeutics an outperform vote.
Invivyd has a net margin of 0.00% compared to Invivyd's net margin of -890.13%. Adaptimmune Therapeutics' return on equity of -93.58% beat Invivyd's return on equity.
Invivyd presently has a consensus target price of $11.33, indicating a potential upside of 388.51%. Adaptimmune Therapeutics has a consensus target price of $2.67, indicating a potential upside of 149.22%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Invivyd is more favorable than Adaptimmune Therapeutics.
70.4% of Invivyd shares are owned by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. 17.9% of Invivyd shares are owned by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Adaptimmune Therapeutics has higher revenue and earnings than Invivyd. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
Invivyd has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500.
Summary
Invivyd beats Adaptimmune Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
